Comparative Pharmacology
Head-to-head clinical analysis: METHAZOLAMIDE versus NEPTAZANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHAZOLAMIDE versus NEPTAZANE.
METHAZOLAMIDE vs NEPTAZANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
Methazolamide is a carbonic anhydrase inhibitor. It decreases intraocular pressure by inhibiting carbonic anhydrase in the ciliary epithelium, reducing aqueous humor secretion. It also has weak diuretic effects due to renal carbonic anhydrase inhibition.
Oral: 50-100 mg two to three times daily.
50 mg orally twice daily, increasing to 50 mg three times daily if needed. Maximum dose: 200 mg daily.
None Documented
None Documented
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Clinical Note
moderateMethazolamide + Etacrynic acid
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid."
Clinical Note
moderateMethazolamide + Bumetanide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide."
Clinical Note
moderateMethazolamide + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide."
Clinical Note
moderateTerminal elimination half-life: 8-12 hours. In renal impairment, half-life may extend to 20-30 hours, requiring dose adjustment.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Renal: 100% as unchanged drug via tubular secretion. No biliary or fecal elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Methazolamide + Indapamide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide."